Combining UCP2 with chemotherapeutic agents as an adjuvant strategy shows potential application value, enhancing effectiveness in inhibiting pancreatic cancer (Dalla et al. 2012; Fiorini et al. 2015). The gene discussed is UCP2; the disease is pancreatic neoplasm.